Terms: = Breast cancer AND BLM, MGC131620, 641, ENSG00000197299, MGC131618, RECQ2, RECQL2, RECQL3, MGC126616, BS
625 results:
1. Evaluating the effects of various ethanolic medicinal plant extracts on metastatic breast cancer proliferation, invasion, and expression of a novel potential drug target; CD82 metastatic suppressor protein, and on in vivo angiogenesis using the ex ovo yolk sac membrane (YSM) assay.
Loggenberg S; Twilley D; Lall N
J Cancer Res Clin Oncol; 2024 May; 150(5):257. PubMed ID: 38753184
[TBL] [Abstract] [Full Text] [Related]
2. Antioxidant and Cytotoxic Properties of
Ivan IM; Olaru OT; Popovici V; Chițescu CL; Popescu L; Luță EA; Ilie EI; Brașoveanu LI; Hotnog CM; Nițulescu GM; Boscencu R; Gîrd CE
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731544
[No Abstract] [Full Text] [Related]
3. Application of Patient-Reported Outcome Measurements in Adult Tumor Clinical Trials in China: Cross-Sectional Study.
Jia Y; Li Q; Zhang X; Yan Y; Yan S; Li S; Li W; Wu X; Rong H; Liu J
J Med Internet Res; 2024 May; 26():e45719. PubMed ID: 38718388
[TBL] [Abstract] [Full Text] [Related]
4. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
[TBL] [Abstract] [Full Text] [Related]
5. Modification of the phenyl ring B of phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates by pyridinyl moiety leads to novel antimitotics targeting the colchicine-binding site.
Ouellette V; Bouzriba C; Chavez Alvarez AC; Hamel-Côté G; Fortin S
Bioorg Med Chem Lett; 2024 Jun; 105():129745. PubMed ID: 38614151
[TBL] [Abstract] [Full Text] [Related]
6. Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.
Vo K; Ladbury C; Yoon S; Bazan J; Glaser S; Amini A
Breast Cancer; 2024 May; 31(3):485-495. PubMed ID: 38507145
[TBL] [Abstract] [Full Text] [Related]
7. A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel blm gene variant.
Ohashi T; Kunimoto H; Nukui J; Teshigawara H; Koyama S; Miyazaki T; Hagihara M; Matsumoto K; Koshimizu E; Tsuchida N; Hamanoue H; Miyatake S; Yachie A; Matsumoto N; Nakajima H
Int J Hematol; 2024 May; 119(5):603-607. PubMed ID: 38489090
[TBL] [Abstract] [Full Text] [Related]
8. Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
Wu Y; Mo H; Xu H; Wang Y; Wang J; Ma F; Xu B
Thorac Cancer; 2024 Apr; 15(12):965-973. PubMed ID: 38480513
[TBL] [Abstract] [Full Text] [Related]
9. Testosterone therapy in females is not associated with increased cardiovascular or breast cancer risk: a claims database analysis.
Agrawal P; Singh SM; Hsueh J; Grutman A; An C; Able C; Choi U; Kohn J; Clifton M; Kohn TP
J Sex Med; 2024 Apr; 21(5):414-419. PubMed ID: 38459625
[TBL] [Abstract] [Full Text] [Related]
10. Cytokine Plasma Levels in breast cancer Patients, Before and After Surgery.
Kontomanolis E; Tsigalou C; Mitrakas A; Gkegka AG; Efraimidou E; Karamanidis D; Nikoletos K; Panagiotis T; Nikoletos N; Giatromanolaki A; Koukourakis MI
J Interferon Cytokine Res; 2024 Mar; 44(3):135-142. PubMed ID: 38386538
[TBL] [Abstract] [Full Text] [Related]
11. Body Contouring Surgery After Bariatric Surgery Improves Long-Term Health-Related Quality of Life and Satisfaction With Appearance: An International Longitudinal Cohort Study Using the BODY-Q.
Dalaei F; de Vries CEE; Poulsen L; Möller S; Kaur MN; Dijkhorst PJ; Thomsen JB; Hoogbergen M; Makarawung DJS; Mink van der Molen AB; Repo JP; Paul MA; Busch KH; Cogliandro A; Opyrchal J; Rose M; Juhl CB; Andries AM; Printzlau A; Støving RK; Klassen AF; Pusic AL; Sørensen JA
Ann Surg; 2024 Jun; 279(6):1008-1017. PubMed ID: 38375665
[TBL] [Abstract] [Full Text] [Related]
12. Who can benefit from postmastectomy radiotherapy among HR+/HER2- T1-2 N1M0 breast cancer patients? An explainable machine learning mortality prediction based approach.
Jin L; Zhao Q; Fu S; Zhang Y; Wu S; Li X; Cao F
Front Endocrinol (Lausanne); 2024; 15():1326009. PubMed ID: 38375194
[TBL] [Abstract] [Full Text] [Related]
13. Long noncoding RNA SNHG1 promotes breast cancer progression by regulating the miR-641/RRS1 axis.
Deng L; Wang J; Song J; Wu Q; Gong Z; Song J; Hou L
Sci Rep; 2024 Feb; 14(1):3265. PubMed ID: 38331968
[TBL] [Abstract] [Full Text] [Related]
14. Comparison performance of the Bayesian Approach with the Weibull and Birnbaum-Saunders distributions in imputation of time-to-event censors.
Shahmirzalou P; Rasekhi A; Jafari Khaledi M; Khayamzadeh M
PLoS One; 2024; 19(1):e0295977. PubMed ID: 38252651
[TBL] [Abstract] [Full Text] [Related]
15. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
Wang H; Yee D; Potter D; Jewett P; Yau C; Beckwith H; Watson A; O'Grady N; Wilson A; Brain S; Pohlmann P; ; Blaes A
Breast Cancer Res Treat; 2024 Apr; 204(3):589-597. PubMed ID: 38216819
[TBL] [Abstract] [Full Text] [Related]
16. Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various types of cancer.
Zhuang Y; Cai Q; Hu X; Huang H
BMC Endocr Disord; 2024 Jan; 24(1):9. PubMed ID: 38212751
[TBL] [Abstract] [Full Text] [Related]
17. Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.
Cobleigh MA; Layng KV; Mauer E; Mahon B; Hockenberry AJ; Abukhdeir AM
Breast Cancer Res Treat; 2024 Apr; 204(2):407-414. PubMed ID: 38153569
[TBL] [Abstract] [Full Text] [Related]
18. Trends and age, sex, and race disparities in time to second primary cancer from 1990 to 2019.
Leung TH; El Helali A; Wang X; Ho JC; Pang H
Cancer Med; 2023 Dec; 12(24):22316-22324. PubMed ID: 38063337
[TBL] [Abstract] [Full Text] [Related]
19. Long non-coding RNA EGOT is associated with
Wang M; Wei Z; Wang S; Feng W; Shang L; Sun X
Aging (Albany NY); 2023 Nov; 15(22):13542-13557. PubMed ID: 38006396
[TBL] [Abstract] [Full Text] [Related]
20. Bisbenzylisoquinoline alkaloid fangchinoline derivative HY-2 inhibits breast cancer cells by suppressing blm DNA helicase.
Zhang W; Yu X; Bao L; He T; Pan W; Li P; Liu J; Liu X; Yang L; Liu J
Biomed Pharmacother; 2023 Dec; 169():115908. PubMed ID: 37988849
[TBL] [Abstract] [Full Text] [Related]
[Next]
